Evidence map›Paper›PMID 38433545›Full record

ReviewProblemy endokrinologii2024

[Fixed ratio combinations GLP-1RA and basal insulin: literature review].

D V Kurkin, D A Bakulin, E I Morkovin, A V Strygin, Ju V Gorbunova, E V Volotova, A I Robertus, I E Makarenko, V B Saparova, R V Drai and 1 more

Open access · diamondAbstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Problemy endokrinologii, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

D V KurkinRussian University of Medicine; Volgograd State Medical University.
D A BakulinRussian University of Medicine.
E I MorkovinVolgograd State Medical University.
A V StryginVolgograd State Medical University.
Ju V GorbunovaRussian University of Medicine.
E V VolotovaVolgograd State Medical University.
A I RobertusRussian University of Medicine.
I E MakarenkoRussian University of Medicine; CJSC «Farm-Holding».
V B SaparovaRussian University of Medicine; CJSC «Farm-Holding».
R V DraiCJSC «Farm-Holding».
V I PetrovVolgograd State Medical University.
Volgograd State Medical University · RUTechnology Holding (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The progressive nature of type 2 diabetes mellitus leads to the need for insulin therapy in a significant proportion of patients. Very often start of insulin therapy in type 2 diabetes mellitus (T2DM) is associated with weight gain and a significant increase of hypoglycemia's risk. However, innovative options, such as fixed ratio combinations of glucagon-like peptide 1 receptor agonists (GLP-1RA) and basal insulin, minimize weight gain and hypoglycemia risks and allow a greater proportion of patients to achieve individual glycemic control goals without compromising safety parameters. This review includes a description of the randomized clinical trials, as well as the results of real clinical practice of the use of two currently existing fixed ration combinations of GLP-1RA and basal insulin - iDegLira and iGlarLixi.

Indexed as

Diabetes Mellitus, Type 2HypoglycemiaHumansInsulinInsulin, Regular, HumanWeight GainInsulinInsulin, Regular, Human

Identifiers

PMID38433545
PMCPMC10926250
OpenAlexW4392296976

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.